Last reviewed · How we verify
NCT06258863
Investigating the Effects of Different Incision Types on Aesthetic Outcomes and Incision-related Complications After Breast Reconstruction Surgery
trial testing incision type in Breast Neoplasm Female in 300 participants. Enrolling by invitation.
18 July 2024
Quick facts
| Lead sponsor | Hubei Cancer Hospital |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 18 July 2023 |
| Primary completion | 18 July 2024 |
| Estimated completion | 18 November 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- incision type
Conditions studied
- Breast Neoplasm Female — all drugs for Breast Neoplasm Female →
Sponsor
Hubei Cancer Hospital
Who can join
18 and older, female only, with Breast Neoplasm Female. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. DATA COLLECTION: About 300 cases of female patients who underwent breast reconstruction at Hubei Cancer Hospital(HBCH) between February 2013 and June 2023 were retrospectively collected. The incision was defined as the mastectomy incision and was grouped by the commonly used inframammary fold incision, lateral chest wall incision, circumareolar incision, and radial incision. The incidence of postoperative incision-related complications was recorded for different incision types; 2. DATA ORGANIZATION: Patients were divided into subgroups based on history of previous breast surgery, location and size of the lump, retention of the nipple-areola complex, timing of reconstruction, and type of the implant. The correlation of each subgroup with incision design is discussed; 3. FOLLOW-UP: Collected cases were followed up by telephone to complete the Breast-Q questionnaire (aesthetic score); 4. DATA ANALYSIS: The incidence of postoperative incision-related complications and aesthetic scores for different incision types were statistically analyzed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06258863
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Neoplasm Female
Currently open trials in the same condition.
- NCT07465523 — A Novel Approach in the Evaluation of Breast Masses With Doppler US · recruiting
- NCT06711523 — Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy · Phase 3 · active not recruiting
- NCT05277935 — Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib · NA · recruiting
- NCT06234137 — A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrot · NA · recruiting
- NCT04812652 — Digitally Distributed Yoga for Women Treated for Breast Cancer · NA · active not recruiting
Other Hubei Cancer Hospital trials
Trials by the same sponsor.
- NCT07188857 — Study on the Relationship Between Opioid Drugs and the Therapeutic Efficacy of Immunotherapy · not yet recruiting
- NCT06402435 — SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer · Phase 2 · recruiting
- NCT06401005 — SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) · Phase 2 · recruiting
- NCT06712524 — Effect of Different Surgical Approaches of Granulomatous Mastitis · NA · recruiting
- NCT06714084 — CNCMT：a Multi-center, Prospective, Single-arm Study · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06258863 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hubei Cancer Hospital
- Last refreshed: 17 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06258863.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing